All Updates

All Updates

icon
Filter
Partnerships
Qiagen collaborates with Eli Lilly to develop diagnostic tool for Alzheimer's disease
Precision Medicine
Sep 4, 2024
This week:
Partnerships
T-Mobile partners with OpenAI to develop AI-powered customer service platform
Generative AI Applications
Today
Partnerships
Runway partners with Lionsgate to develop AI video tools using studio's movie catalog
Generative AI Applications
Yesterday
Funding
QMill raises EUR 4 million in seed funding to provide quantum computing industrial applications
Quantum Computing
Yesterday
Product updates
QuiX Quantum launches 'Bia' quantum cloud computing service for quantum solutions
Quantum Computing
Yesterday
Partnerships
Oxford Ionics and Infineon Technologies partner to build portable quantum computer for Cyberagentur
Quantum Computing
Yesterday
Partnerships
Product updates
Tencent Ai Lab launches EzAudio AI for text-to-audio generation with Johns Hopkins University
Foundation Models
Yesterday
Funding
TON secures USD 30 million in investment from Bitget and Foresight Ventures
Web3 Ecosystem
Yesterday
Funding
Hemi Labs raises USD 15 million in funding to launch blockchain network
Web3 Ecosystem
Yesterday
Product updates
Fivetran launches Hybrid Deployment for data pipeline management
Machine Learning Infrastructure
Yesterday
Product updates
Fivetran launches Hybrid Deployment for data pipeline management
Data Infrastructure & Analytics
Yesterday
Precision Medicine

Precision Medicine

Sep 4, 2024

Qiagen collaborates with Eli Lilly to develop diagnostic tool for Alzheimer's disease

Partnerships

  • QIAGEN has entered a partnership with pharmaceutical firm Eli Lilly and Company to develop a diagnostic tool for Alzheimer's disease.

  • The partnership expects to produce the first commercially available in-vitro diagnostic (IVD) panel for identifying APOE genetic variants, which have a role in the diagnosis of Alzheimer’s disease. Integrated with QIAGEN’s QIAstat-Dx platform, the IVD panel is claimed to be able to provide results within an hour to aid speedy treatment decisions. 

  • Analyst Quick Take: In August 2024 , Qiagen also collaborated with pharmaceutical company AstraZeneca to develop companion diagnostics for the latter’s upcoming therapies for chronic diseases. QIAGEN will create and validate a genotyping assay using its QIAstat-Dx testing platform to detect and differentiate between multiple biomarkers, claiming to provide results within an hour.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.